A5102728123- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Pulsars and Gravitational Waves Research
- Systemic Lupus Erythematosus Research
- HIV Research and Treatment
- Cosmology and Gravitation Theories
- Gamma-ray bursts and supernovae
- Geophysics and Gravity Measurements
- Renal Transplantation Outcomes and Treatments
- Biochemical and Molecular Research
- Liver Disease and Transplantation
- Astrophysical Phenomena and Observations
- Insects and Parasite Interactions
- Neonatal Health and Biochemistry
- Cancer Treatment and Pharmacology
- Protein purification and stability
- Bipolar Disorder and Treatment
- Orthopaedic implants and arthroplasty
- Brucella: diagnosis, epidemiology, treatment
- Statistical Methods in Clinical Trials
- Schizophrenia research and treatment
- Anesthesia and Pain Management
AbbVie (United States)
2014-2023
Université Paris-Saclay
2018-2022
Institut National de Physique Nucléaire et de Physique des Particules
2019-2021
Centre National de la Recherche Scientifique
2019-2021
Laboratoire de Physique des 2 Infinis Irène Joliot-Curie
2021
Martin Luther University Halle-Wittenberg
2020
Université Paris-Sud
2017-2019
Abbott Fund
2013
Abbott (United Kingdom)
2013
Hôpital Xavier Arnozan
2008
The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir or without ribavirin has shown efficacy in inducing a sustained virologic response phase 2 study involving patients hepatitis C virus (HCV) genotype 1 infection. We conducted two 3 trials to examine the safety this previously untreated HCV infection no cirrhosis.
There is a need for interferon-free treatment regimens hepatitis C virus (HCV) infection. The goal of this study was to evaluate ABT-450, potent HCV NS3 protease inhibitor, combined with low-dose ritonavir (ABT-450/r), in addition ABT-333, nonnucleoside NS5B polymerase and ribavirin, the
Background & AimsAlthough hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied this population. We investigated the safety and efficacy of ombitasvir co-formulated paritaprevir ritonavir, administered dasabuvir (with or without ribavirin) a prospective study stage 4 5 chronic kidney disease (CKD).MethodsWe performed single-arm, multicenter treatment-naïve...
An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), nonnucleoside polymerase ABT-333, and ribavirin showed efficacy against hepatitis C virus (HCV) in a pilot study involving patients HCV genotype 1 infection. The addition another potent agent, NS5A ABT-267, may improve efficacy, especially difficult-to-treat patients. This was designed to evaluate multiple regimens direct-acting antiviral agents infection who had not received therapy previously or no...
Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates initiation and completion interferon-based therapies. This study evaluated efficacy, safety, pharmacokinetics 12-week all-oral regimen ombitasvir/paritaprevir/ritonavir dasabuvir+ribavirin in HCV genotype 1-infected on stable opioid replacement therapy.This was phase II, multicenter, open-label, single-arm treatment-naïve or peginterferon/ribavirin treatment-experienced methadone...
The development of direct-acting antiviral agents is a promising therapeutic advance in the treatment hepatitis C virus (HCV) infection. However, rapid emergence drug resistance can limit efficacy and lead to cross-resistance among members same class. ABT-450 an efficacious inhibitor HCV NS3/4A protease, with 50% effective concentration values 1.0, 0.21, 5.3, 19, 0.09, 0.69 nM against stable replicons NS3 protease from genotypes 1a, 1b, 2a, 3a, 4a, 6a, respectively. In vitro, most common...
AVIATOR, a phase 2 clinical trial, evaluated ritonavir-boosted paritaprevir (a protease inhibitor), ombitasvir (an NS5A and dasabuvir nonnucleoside polymerase inhibitor) (the three-drug [3D] regimen) with or without ribavirin (RBV) for 8, 12, 24 weeks in 406 HCV genotype 1 (GT1)-infected patients. The rate of sustained virologic response after treatment ranged from 88% to 100% across the arms 3D regimen RBV; 20 GT1a-infected patients GT1b-infected patient experienced failure (5.2%). Baseline...
ABT-450, ombitasvir, and dasabuvir are direct-acting antiviral agents (DAAs) that have been developed for combination treatment of chronic hepatitis C virus (HCV) infection. Because these DAAs metabolic transporter profiles overlap with cyclosporine tacrolimus disposition, there is potential drug interactions. Two Phase 1 studies assessed effects ABT-450 (150 mg coadministered ritonavir 100 once daily), ombitasvir (25 (400 twice daily) on the pharmacokinetics, safety, tolerability a single...
The introduction of highly potent direct-acting combination therapies for HCV have negated the role response-guided therapy and reduced treatment monitoring. However, there remains a need to identify patients who are actively infected with discriminate those achieved sustained virological response (SVR) from fail achieve SVR.A total 1,678 plasma samples 631 subjects enrolled in AbbVie's SAPPHIRE I trial (NCT01716585) were tested blinded fashion Abbott core antigen (cAg) assay results...
In light of the advances in HCV therapy, simplification diagnosis confirmation, pre- treatment diagnostic workup and monitoring is required to ensure broad access interferon-free therapies. core antigen (HCV cAg) testing rapid, giving results approximately 60min, less expensive than RNA methods. While extensive data on analytical performance cAg relative or comparisons longitudinal studies patients interferon based (response guided) therapy there very limited receiving all-oral free...
We analyzed phase 3 trial data of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) ± ribavirin (RBV) in genotype 1 chronic hepatitis C patients to investigate the impact 3D RBV on renal, cardiovascular metabolic extrahepatic manifestations (EHMs), including persistency 52 weeks post treatment differential by EHM disease severity.Estimated glomerular filtration rate (eGFR), fasting triglyceride glucose values from clinical trials were used assess EHMs, respectively. Two placebo-controlled...
In 247 subjects with hepatitis C virus genotype 1 infection treated the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance a sustained virologic response at 12 24 weeks supports use earlier time point as primary efficacy endpoint for trials this regimen.
Circulating microRNAs (miRNA) have been intensely investigated as biomarkers in disease and therapy. Several studies identified miR-122 an important regulator of HCV replication. The effect new therapies that directly target the replication life cycle on circulating microRNA levels has not elucidated. We performed expression profiling miRNA serum subjects treated with direct-acting antiviral agents (DAAs). Serum were evaluated from two GT1-infected treatment-naïve prior nonresponders to...
IntroductionHepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ribavirin (RBV) 2 phase 3, open-label, multicenter studies stage 4 or 5 chronic kidney disease (CKD).MethodsRUBY-I, Cohort enrolled treatment-naïve -experienced HCV genotype (GT) 1a 1b infection, without cirrhosis. Patients received 12 weeks (24 for GT1a cirrhosis) OBV/PTV/r + DSV; all...
Summary The role of the endogenous interferon ( IFN ) system has been well characterized during ‐based therapy for chronic hepatitis C virus HCV infection; less is known direct‐acting antivirals DAA s). In this phase 3b open‐label study, we assessed changes in ‐stimulated genes ISG s) non‐cirrhotic treatment‐naïve or peg / RBV ‐experienced ‐ GT 1a‐infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir ribavirin (Pr OD R) 12 weeks. expression was quantified from peripheral...
In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates sustained virologic response (SVR). However, these regimens have not been investigated adolescents. This ongoing, open‐label, phase 2/3 study evaluated the pharmacokinetics, safety, efficacy OBV/PTV/r+DSV±RBV for 12 weeks adolescents infected HCV genotype (GT) 1 cirrhosis (part 1) safety OBV/PTV/r±DSV±RBV 24 GT1...
The present study sought to investigate the prevalence of hepatitis C virus (HCV) among men who have sex with (MSM) seen at a community health center, and examine risk factors associated infection. population included 218 MSM were screened for HCV infection during routine clinic visits from May through December, 2001. Eighty-four percent those (n = 183) agreed complete self-report questionnaire assessing drug use, sexual practices, medical history. Participants ranged in age 22 54 years....
Application of response-guided therapy (RGT) rules to the treatment HCV infection with pegylated interferon-α2a and ribavirin, direct-acting antivirals (DAAs) such as NS3/4A protease inhibitors (PIs) boceprevir telaprevir, relies on determination viral genotype on-treatment RNA level. Currently there are few data available regarding clinical impact analytical differences that exist between different quantification assays decisions those involved in RGT.We sought ascertain concordance two...